黃岸 蒙虎 關(guān)林 蒙一純
[摘要]大麻二酚(Cannabidiol, CBD)為大麻提取物中的一種非成癮性活性成分,是目前研究最熱門(mén)的植物源性大麻素之一。其能夠修復(fù)紫外線(xiàn)、環(huán)境污染物或其它來(lái)源導(dǎo)致的自由基受損,經(jīng)皮膚吸收后可起到舒緩肌膚、維持皮膚最佳狀態(tài)的功能。CBD可抑制皮脂腺細(xì)胞的皮脂分泌和增殖、多種促炎細(xì)胞因子的產(chǎn)生,并已被證明具有抗氧化、抗菌、鎮(zhèn)痛以及抗炎、調(diào)節(jié)細(xì)胞周期和免疫細(xì)胞等作用。另外,CBD還可與內(nèi)源性大麻素系統(tǒng)受體產(chǎn)生作用以發(fā)揮其優(yōu)異特性。本文就CBD在抗氧化和抗紫外線(xiàn)、抗炎和免疫調(diào)節(jié)、細(xì)胞增殖和抗凋亡、抗菌、鎮(zhèn)痛以及與內(nèi)源性大麻素系統(tǒng)的作用機(jī)理等方面進(jìn)行詳細(xì)綜述。
[關(guān)鍵詞]大麻二酚;抗氧化;抗紫外線(xiàn);抗炎;細(xì)胞增殖;抗菌;鎮(zhèn)痛
[中圖分類(lèi)號(hào)]R758? ? [文獻(xiàn)標(biāo)志碼]A? ? [文章編號(hào)]1008-6455(2022)03-0181-04
The Function of Cannabidiol in Skin Health
HUANG An, MENG Hu, GUAN Lin, MENG Yichun
(Beijing Mengbring Bio-sci-Tec. Co., ltd, Beijing 101105, China)
Abstract: Cannabidiol (CBD), a non-addictive active ingredient in cannabis extract, is one of the most popular plant-derived cannabinoids in research at present.It can repair free radical damage caused by ultraviolet light, environmental pollutants or other sources, and can soothe the skin and maintain the best condition of the skin after absorption. CBD can inhibit sebum secretion and proliferation of sebaceous gland cells and the production of a variety of pro-inflammatory cytokines, and has been shown to have antioxidant, antibacterial, analgesic and anti-inflammatory effects,as well as to regulate cell cycle and immune cells. In addition, CBD can also interact with receptors of the endocannabinoid system to exert its excellent properties. In this paper, CBD's role in antioxidant and UV resistance, anti-inflammatory and immunomodulatory, cell proliferation and anti-apoptosis, antibacterial, analgesic effect,and the mechanism of action between CBD and the endocannabinoid system will be reviewed in detail.
Key words: cannabidiol; antioxidant; UV resistance; anti-inflammatory; cell proliferation; antibacterial; analgesic
大麻二酚(Cannabidiol, CBD)又名為多酚樹(shù)脂,是大麻的提取物之一。千百年來(lái)大麻素作為草藥成分,在醫(yī)學(xué)領(lǐng)域發(fā)揮著重要作用,但近百年來(lái)由于大麻主要提取物之一的大麻素主要成分-四氫大麻酚(簡(jiǎn)稱(chēng)Δ9-THC),作為神經(jīng)依賴(lài)性毒品對(duì)人體健康和社會(huì)穩(wěn)定具有破壞性影響,使人們對(duì)大麻談虎色變,也使人們長(zhǎng)期以來(lái)忽視了對(duì)與Δ9-THC化學(xué)結(jié)構(gòu)式相似的CBD的研究[1]。CBD是工業(yè)大麻葉提取物全譜油中最豐富的大麻素,其應(yīng)用于皮膚健康,主要通過(guò)CBD作用于內(nèi)源性大麻素系統(tǒng),從而發(fā)揮其抗氧化和抗紫外線(xiàn)、抗炎和免疫調(diào)節(jié)、細(xì)胞增殖和抗凋亡、抗菌以及鎮(zhèn)痛等功能[2]。
1? CBD的作用
CBD已經(jīng)成為皮膚健康產(chǎn)品中所摻加成分的一種趨勢(shì),其被證實(shí)參與了皮膚中的某些生化途徑[3],如圖1所示。
1.1 抗氧化和抗紫外線(xiàn):CBD已被證明具有抗氧化活性[4],其分子式是C21H30O2,摩爾質(zhì)量為314.46 g/mol,它的化學(xué)結(jié)構(gòu)式如圖2所示:CBD的生物化學(xué)活性主要是由于酚環(huán)(B)中C-1'和C-5'位置上的羥基,以及環(huán)己烯環(huán)(A)中C-1位置上的甲基和酚環(huán)(B)中C-3'位置上的戊烷基鏈。而開(kāi)環(huán)C-4位置是不活躍的。由于酚環(huán)(B)中C-1'和C-5'位置上的羥基,CBD還可以通過(guò)氫鍵與氨基酸,如蘇氨酸、酪氨酸、谷氨酸或谷氨酰胺等結(jié)合[5]。CBD具有廣泛的生物活動(dòng),如抗氧化活性,其在預(yù)防、治療與氧化還原失衡等相關(guān)的皮膚疾病方面已被證實(shí)[6-8]。CBD可通過(guò)修飾氧化劑和抗氧化劑的水平和活性來(lái)影響氧化還原平衡,可像其它抗氧化劑一樣,阻斷自由基鏈反應(yīng),捕獲自由基或者將其轉(zhuǎn)化為活性較低形式。這些反應(yīng)產(chǎn)生的自由基具有許多共振結(jié)構(gòu)的特點(diǎn),其中未配對(duì)電子主要存在于酚環(huán)結(jié)構(gòu),說(shuō)明酚環(huán)上的羥基是CBD抗氧化活性的主要來(lái)源[9]。
CBD的抗氧化活性開(kāi)始于蛋白質(zhì)轉(zhuǎn)錄,通過(guò)激活對(duì)氧化還原反應(yīng)敏感的轉(zhuǎn)錄因子,即核紅素2相關(guān)因子(Nrf2)[10],它負(fù)責(zé)包括抗氧化基因在內(nèi)的細(xì)胞保護(hù)基因的轉(zhuǎn)錄[11],從而產(chǎn)生抗氧化活性。與α-生育酚或維生素C相比,CBD表現(xiàn)出更強(qiáng)的抗氧化活性(30%~50%)[6]。初步研究表明,CBD有助于保持皮膚平衡,并解決常見(jiàn)問(wèn)題如皮膚衰老、干燥等,當(dāng)與其他活性成分協(xié)同作用時(shí),可增強(qiáng)其抗氧化作用[12]。研究表明[13],皮膚在受到刺激條件下,CBD可作為活性氧(Reactive oxygen species,ROS)的清除劑和細(xì)胞的抗氧化劑。紫外線(xiàn)照射下的角質(zhì)形成細(xì)胞顯示CBD通過(guò)刺激轉(zhuǎn)錄因子Nrf2和抑制促炎轉(zhuǎn)錄因子NF-kB,來(lái)增加抗氧化酶的活性[14]。紫外線(xiàn)的輻射對(duì)人類(lèi)皮膚具有破壞性作用,其可通過(guò)ROS的直接形成和改變細(xì)胞組分(如:蛋白質(zhì)、脂質(zhì)和核酸)的結(jié)構(gòu),從而影響細(xì)胞功能,CBD則對(duì)因暴露在陽(yáng)光下而受到紫外線(xiàn)誘導(dǎo)產(chǎn)生氧化應(yīng)激的皮膚細(xì)胞具有保護(hù)作用[15]。另外,黑色素可以保護(hù)皮膚免受紫外線(xiàn)照射和氧化應(yīng)激,防止DNA損傷。研究顯示[16]CBD可激活p42/44 MAPK和p38 MAPK信號(hào)通路,增加相關(guān)轉(zhuǎn)錄因子(Microphthalmia-associated transcription factor,MITF)基因的表達(dá),從而調(diào)節(jié)黑色素生成,這項(xiàng)研究顯示CBD可能有改善色素減退性皮膚病的潛力,因此,CBD具有抗紫外線(xiàn)作用。
1.2 抗炎和免疫調(diào)節(jié):CBD具有抗炎活性,并能調(diào)節(jié)細(xì)胞周期和免疫細(xì)胞功能[4],其在炎癥性皮膚病方面具有很好的治療潛力。CBD對(duì)原位人皮脂腺具有顯著抑制作用,研究者通過(guò)應(yīng)用革蘭陰性菌細(xì)胞壁的脂多糖和革蘭陽(yáng)性細(xì)胞壁的脂磷壁酸模擬皮脂腺細(xì)胞感染,結(jié)果顯示CBD能顯著抑制IL1B、IL6和TNFA mRNA的表達(dá),具有普遍抗炎作用[17-18]。因此,CBD可從多種途徑抑制尋常痤瘡的發(fā)展,并表現(xiàn)為有效的抗痤瘡功能。含有CBD的產(chǎn)品在治療銀屑病、變應(yīng)性接觸性皮炎和特應(yīng)性皮炎方面也有效果[19],其抗炎特性可能是因?yàn)棣?干擾素和角質(zhì)化細(xì)胞產(chǎn)生的細(xì)胞因子的減少,從而起到改善各種炎癥性皮膚病的作用。研究顯示,銀屑病與T細(xì)胞介導(dǎo)的炎癥反應(yīng)失調(diào)有關(guān),CBD具有調(diào)節(jié)免疫細(xì)胞的功能,CBD可以通過(guò)骨髓來(lái)源的抑制性細(xì)胞(Myeloid-derived suppressor cells,MDSCs)來(lái)抑制T細(xì)胞的功能活性[20],其能降低Th17細(xì)胞的功能,減少炎性因子的分泌[21]。通過(guò)體外研究和臨床觀察,對(duì)銀屑病和特應(yīng)性皮炎患者使用含CBD的外用軟膏,結(jié)果顯示,皮膚狀況得以改善且未觀察到刺激和過(guò)敏反應(yīng)[22],表明CBD有益于銀屑病和特應(yīng)性皮炎的治療。研究者[23]通過(guò)聚肌胞苷酸刺激HaCaT細(xì)胞,模擬變應(yīng)性接觸性皮炎的體外模型,結(jié)果顯示CBD降低了HaCaT細(xì)胞中的單核細(xì)胞趨化蛋白-2(Monocyte chemotactic protein-2,MCP-2)、IL6、IL-8和TNF-α的蛋白表達(dá)水平。因此,CBD對(duì)治療變應(yīng)性接觸性皮炎有積極作用。
1.3 細(xì)胞增殖和抗凋亡:CBD已被證明能夠抑制多種促炎細(xì)胞因子的產(chǎn)生,如腫瘤壞死因子α和白細(xì)胞介素-1β等,還能抑制免疫細(xì)胞增殖、活化、成熟、遷移和抗原呈遞[4]。局部應(yīng)用CBD可增加表皮厚度,并增加細(xì)胞角質(zhì)蛋白KRT16和KRT17的表達(dá),這兩種蛋白與角質(zhì)形成細(xì)胞的增殖和傷口愈合有關(guān)[24]。CBD具有抑制皮脂腺細(xì)胞的皮脂分泌、增殖,還能抑制角質(zhì)形成細(xì)胞的過(guò)度增殖[17]。CBD還可能發(fā)揮DNA甲基轉(zhuǎn)移酶增強(qiáng)劑的作用,作為轉(zhuǎn)錄抑制因子,調(diào)控角質(zhì)形成細(xì)胞的增殖和分化[25]。另外,曾有報(bào)道CBD的抗凋亡活性,表明CBD對(duì)細(xì)胞存活有積極作用[8]。因此,CBD能夠舒緩和護(hù)理皮膚,減少炎癥,促進(jìn)傷口愈合。
1.4 抗菌:CBD作為從大麻中提取的一種植物大麻素已被證實(shí)具有抗菌活性。有研究者[26]驗(yàn)證了CBD對(duì)革蘭氏陽(yáng)性菌的耐甲氧西林金黃色葡萄球菌(Methicillin-resistant staphylococcus aureus, MRSA)的抗菌作用,其還對(duì)糞腸球菌(E.faecalis)、單核細(xì)胞增生李斯特氏菌(L.monocytogenes)和耐甲氧西林表皮葡萄球菌(Methicillin-resistant staphylococcus epidermidis,MRSE)的抗菌作用。CBD對(duì)MRSA、單核細(xì)胞增生李斯特氏菌和MRSE的最低抑菌濃度(Minimum inhibitory concentration,MIC)為4 μg/ml,對(duì)糞腸球菌的MIC為8 μg/ml,說(shuō)明革蘭氏陽(yáng)性菌對(duì)CBD敏感。另外,研究者對(duì)比了CBD和桿菌肽(Bacitracin,BAC)對(duì)不同菌株的抗菌活性,其MIC見(jiàn)表1。
從表1中可見(jiàn),在不同的革蘭氏陽(yáng)性菌中,與單獨(dú)使用BAC的MIC相比,在1/2×CBD的MIC情況下,BAC的MIC降低了8~64倍。并測(cè)定了各革蘭氏陽(yáng)性菌的抑菌濃度指數(shù)(Fractional Inhibitory Concentration, FIC),結(jié)果顯示MRSA和MRSE的FIC指數(shù)均為0.5,而糞腸球菌的則為0.375,這表現(xiàn)出CBD和BAC聯(lián)合使用時(shí)的抗菌性具有協(xié)同作用。評(píng)估隨著時(shí)間的延長(zhǎng),如超過(guò)24 h的細(xì)菌生長(zhǎng)情況表明CBD和BAC的聯(lián)合使用同樣對(duì)上述4種菌株具有抗菌活性[28]。
1976年,Klingeren和Ham進(jìn)行的關(guān)于Δ9-THC和CBD抗菌活性研究[29],所采用的菌株為革蘭氏陽(yáng)性菌的金黃色葡萄球菌、化膿性鏈球菌、米勒鏈球菌、糞腸球菌以及革蘭氏陰性菌的傷寒沙門(mén)氏菌和變形桿菌。這兩種化合物對(duì)所有革蘭氏陽(yáng)性菌均顯示出顯著的抗菌活性,其與Krejci等的結(jié)果一致,但對(duì)革蘭氏陰性菌無(wú)顯著活性[30],如表2所示。
從表2可見(jiàn),與Δ9-THC對(duì)革蘭氏陽(yáng)性菌的抗菌活性MIC相比,CBD的MIC均相等或較小。其中CBD對(duì)金黃色葡萄球菌的MIC為1~5 μg/ml、化膿性鏈球菌的MIC為2 μg/ml、米勒鏈球菌的MIC為1 μg/ml、糞腸球菌的MIC為5 μg/ml。
1.5 鎮(zhèn)痛:CBD具有鎮(zhèn)痛作用,其可以與TRPV1相互作用并使其脫敏,TRPV1是一種表達(dá)于神經(jīng)纖維、角質(zhì)形成細(xì)胞和內(nèi)皮細(xì)胞中的疼痛受體[14]。由于CBD可調(diào)節(jié)疼痛感知,且有望用于治療瘙癢癥[19,23],有推測(cè)認(rèn)為CBD可通過(guò)減輕慢性疼痛、改善瘙癢感,從而減輕大皰性表皮松解癥(Epidermolysis bullosa,EB)的癥狀[31]。臨床研究顯示,EB患者在使用CBD后的短時(shí)間內(nèi),改善效果即可出現(xiàn),特別是減輕疼痛、減少水皰及傷口的快速愈合方面[32]。
2? CBD與內(nèi)源性大麻素系統(tǒng)的作用機(jī)理
內(nèi)源性大麻素系統(tǒng)(Endocannabiniol system,ECS),是機(jī)體內(nèi)部存在的成分網(wǎng)絡(luò),主要負(fù)責(zé)調(diào)節(jié)和平衡機(jī)體對(duì)某些觸發(fā)的反應(yīng),如新陳代謝、免疫力、細(xì)胞間的通訊等,有人稱(chēng)其為機(jī)體的第十大系統(tǒng)。ECS參與了皮膚修復(fù)、免疫防御、炎癥反應(yīng)等過(guò)程。ECS包括內(nèi)源性大麻素受體(CB)和內(nèi)源性大麻素,體內(nèi)存在兩種大麻素受體:CB1和CB2,研究表明CBD與CB1和CB2有結(jié)合能力[33]。而外源性合成或生物提取的大麻素物質(zhì)也可以特異性結(jié)合體內(nèi)的CB受體,從而激活或調(diào)解ECS[34]。
研究表明,作為一種植物大麻素,CBD可能會(huì)對(duì)ECS的生物活性起到支持性作用,它可通過(guò)與CB受體的相互作用增加大麻素的含量,影響大麻素信號(hào)傳導(dǎo),從而調(diào)節(jié)ECS的活性[35-36]。如內(nèi)源性大麻素一樣,CBD的抗氧化活性,一定程度上與它對(duì)受體的作用有關(guān)。根據(jù)濃度的不同,CBD可以對(duì)受體(CB1和CB2)具有激活、拮抗或抑制作用[37-39]。CBD可通過(guò)大麻素CB受體依賴(lài)和非依賴(lài)途徑起作用,其對(duì)CB1和CB2具有較低的親和力。因此,CBD具有抗鎮(zhèn)靜、抗精神紊亂和抗焦慮的作用,且其高劑量時(shí)不會(huì)產(chǎn)生精神活性,無(wú)致幻作用[40]。
CBD已被證明是CB1受體的弱興奮劑[41]。CBD可能通過(guò)作用于CB1受體,調(diào)節(jié)表皮分化基因(即角蛋白、外皮蛋白和轉(zhuǎn)谷氨酰胺酶)的表達(dá),從而調(diào)控角質(zhì)形成細(xì)胞的增殖和分化[25]。另外,CB1受體的激活增加了ROS的產(chǎn)生和促炎癥反應(yīng)[42]。此外,研究表明CBD是CB1受體的負(fù)向調(diào)節(jié)劑[43]。不管CBD對(duì)CB1受體的作用如何,CBD都是CB2受體的弱興奮劑[44],但也有研究表明CBD可能表現(xiàn)出CB2受體的逆向激動(dòng)作用[45]。重要的是,CB2的激活可導(dǎo)致ROS和TNF-α(腫瘤壞死因子)水平下降,從而減少氧化應(yīng)激反應(yīng)和炎癥[42]。因此,CBD可能通過(guò)CB受體間接提高抗炎和抗氧化作用。
3? CBD的應(yīng)用進(jìn)展及展望
通過(guò)上述對(duì)于CBD功能的描述,含有CBD的產(chǎn)品可廣泛適用于不同種族、不同性別、不同年齡的敏感性、色素分布失衡、痤瘡、粉刺、瘙癢、紅血絲等各類(lèi)膚質(zhì)。其功能包括:①保濕作用;②抗菌作用;③止痛作用;④消炎作用;⑤抗過(guò)敏作用;⑥抗紫外線(xiàn)損傷作用;⑦抗衰老祛皺紋作用;⑧抑制皮脂腺過(guò)度分泌作用,且還具有減輕激光術(shù)后疼痛、減少出血、消除水腫、避免細(xì)菌感染等作用。CBD的這些優(yōu)異功能有望鼓勵(lì)制造商開(kāi)發(fā)含有該成分的產(chǎn)品,從而推動(dòng)未來(lái)幾年的護(hù)膚品市場(chǎng)。
目前,國(guó)外已經(jīng)上市的多款含有CBD的皮膚護(hù)理產(chǎn)品,如CBD & HYALURONIC FACIAL pH BALANCE TONER(CBD爽膚水)、CBD ACTIVE FIRMING ANTI AGEING MASK(CBD活性緊致抗衰老面膜)、CBD & HYALURONIC CLEANSING MILK(CBD潔面乳)等。而在國(guó)內(nèi)已有經(jīng)藥監(jiān)局批準(zhǔn)的含CBD醫(yī)療器械護(hù)膚產(chǎn)品,有研究者[46-47]研發(fā)了含有CBD的醫(yī)用冷敷貼和液體敷料,這兩款醫(yī)療器械產(chǎn)品可對(duì)皮膚起到較好的護(hù)理作用。
[參考文獻(xiàn)]
[1]Russo,Ethan B.Cannabidiol claims and misconceptions[J].Trends Pharmacol Sci,2017,38(5):198-201.
[2]Anwar F,Latif S,Ashraf M.Analytical characterization of hemp(Cannabis sativa) seed oil from different agroecological zones of Pakistan[J].J Am Oil Chem Soc,2006,83(4):323-329.
[3]Pertwee R G.Pharmacology of cannabinoid CB1 and CB2 receptors[J].Pharmacol Ther,1997,74(2):129-180.
[4]Giacoppo S, Galuppo M,Pollastro F,et al.A new formulation of cannabidiol in cream shows therapeutic effects in a mouse model of experimental autoimmune encephalomyelitis[J].DARU,2015,23(1):48.
[5]Elmes M W,Kaczocha M,Berger WT,et al.Fatty acid-binding proteins(FABPs) are intracellular carriers for Δ9-tetrahydrocannabinol(THC) and cannabidiol(CBD)[J].J Bio Chem,2015,290(14):8711-8721.
[6]Iffland K,Grotenhermen F.An update on safety and side effects of cannabidiol:a review of clinical data and relevant animal studies[J].Cannabis? Cannabinoid Res,2017,2(1):139-154.
[7]Peres F F,Lima A C,Hallak J E C,et al.Cannabidiol as a promising strategy to treat and prevent movement disorders[J].Front Pharmacol,2018,9:482.
[8]Kappel D S V, Souza D F B, Lacerda G R C, et al.Antiapoptotic effects of cannabidiol in an experimental model of cognitive decline induced by brain iron overload[J].Transl Psychiat,2018,8(1):176-184.
[9]Borges R S,Batista J,Viana R B,et al.Understanding the molecular aspects of tetrahydrocannabinol and cannabidiol as antioxidants[J].Molecules,2013,18(10): 12663-12674.
[10]Ana J,Maciej P,Ewa K,et al.Microarray and pathway analysis reveal distinct mechanisms underlying cannabinoid-mediated modulation of LPS-induced activation of BV-2 microglial cells[J].PloS One,2013,8(4):61462.
[11]Sandra V,Anne S,Michael P,et al.The master regulator of anti-oxidative responses[J].Int J Mol Sci,2017,18(12):2772.
[12]Elsa N.CBD and its skin care benefits[J].COSSMA,2019,20(7):?48-49.
[13]Massi P,Vaccani A,Bianchessi S,et al.The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells[J].Cell Mol Life Sci,2006,63(17):2057-2066.
[14]Jastrzab A,Gegotek A,Skrzydlewska E.Cannabidiol regulates the expression of keratinocyte proteins involved in the inflammation process through transcriptional regulation[J].Cells,2019,8(8):827.
[15]Gegotek A,Biernacki M,Ambrozewicz E,et al.The cross-talk between electrophiles, antioxidant defence and the endocannabinoid system in fibroblasts and keratinocytes after UVA and UVB irradiation[J].J Dermatol Sci,2016,81(2):107-117.
[16]Hwang Y S,Kim Y J,Kim M O,et al.Cannabidiol upregulates melanogenesis through CB1 dependent pathway by activating p38 MAPK and p42/44 MAPK[J].Chem Biol Interact,2017,273:107-114.
[17]Oláh A,Tóth B I,Borbíró I,et al.Cannabidiol exerts sebostatic and antinflammatory effects on human sebocytes[J].J Clin Invest,2014,124(9):3713-3724.
[18]Oláh A,Bíró T.Targeting cutaneous cannabinoid signaling in inflammation-A "high"-way to heal[J].Ebiomedicine,2017,16:3-5.
[19]Mounessa J S,Siegel J A,Dunnick C A,et al.The role of cannabinoids in dermatology[J].J Am Acad Dermatol,2017,77(1):188-190.
[20]Hegde V L,Singh U P,Nagarkatti P S,et al.Critical role of mast cells and peroxisome proliferator-activated receptor γ in the induction of myeloid-derived suppressor cells by marijuana cannabidiol in vivo[J].J Immunol,2015,194(11):5211-5222.
[21]Kozela E,Juknat A,Gao F,et al.Pathways and gene networks mediating the regulatory effects of cannabidiol,a nonpsychoactive cannabinoid,in autoimmune T cells[J].J Neuroinflamm,2016,13(1):136.
[22]Palmieri B,Laurino C,Vadalà M.A therapeutic effect of CBD-enriched ointment in inflammatory skin diseases and cutaneous scars[J].Clin Ter,2019,170(2):93-99.
[23]Petrosino S,Verde R,Vaia M,et al.Anti-inflammatory properties of cannabidiol,a nonpsychotropic cannabinoid,in experimental allergic contact dermatitis[J].J Pharmacol Exp Ther,2018,365(3):652-663.
[24]Laura C,Víctor G,Martín G R,et al.Cannabidiol Induces Antioxidant Pathways in Keratinocytes by Targeting BACH1[J].Redox Biol,2020,28:101321.
[25]Pucci M,Rapino C,F(xiàn)rancesco AD,et al.Epigenetic control of skin differentiation genes by phytocannabinoids[J].Brit J Pharmacol,2013,170(3):581- 591.
[26]Appendino G,Gibbons S,Giana A,et al.Antibacterial cannabinoids from cannabis sativa:a structure-activity study[J].J Nat Prod,2008,71(8):1427-1430.
[27]Odds F C.Synergy,antagonism and what the chequerboard puts between them[J].J Antimicrob Chemoth,2003,52(1):1.
[28]Wassmann C S,Hjrup P,Klitgaard J K.Cannabidiol is an effective helper compound in combination with bacitracin to kill Gram-positive bacteria[J].Sci Rep,2020,10(1):4112-4112.
[29]Klingeren B V,Ham M T.Antibacterial activity of delta 9-tetrahydrocannabinol and cannabidiol[J].Antonie Van Leeuwenhoek,1976,42(1):9-12.
[30]Krejci Z.Hanf(Cannabis sativa)-antibiotisches heilmittelung 3.mitteilung: isolierung und konstitution zweier aus cannabis sativa gewonnener saure[J].Pharmazie,1958,12:439-443.
[31]Cianfarani F,Zambruno G,Castiglia D,et al.Pathomechanisms of altered wound healing in recessive dystrophic epidermolysis bullosa[J].Am J Pathol,2017,187(7):1445-1453.
[32]Chelliah M P,Zinn Z,Khuu P,et al.Self-initiated use of topical cannabidiol oil? ?for epidermolysis bullosa[J].Pediatr Dermatol,2018,35(4):224-227.
[33]蔣鴻雁,張瑞林,曹艷,等.大麻二酚在醫(yī)學(xué)上的應(yīng)用前景[J].昆明醫(yī)科大學(xué)學(xué)報(bào),2021,42(2):147-152.
[34]Bíró T,Tóth B l,Haskó G,et al.The endocannabinoid system of the skin in health and disease:novel perspectives and therapeutic opportunities[J].Trends Pharmacol Sci,2009,30(8):411-420.
[35]Lim K,See YM,Lee J.A systematic review of the effectiveness of medical cannabis for psychiatric,movement and neurodegenerative disorders[J].Clin Psychopharmacol Neurosci,2017,15(4):301-312.
[36]Bih C I,Chen T,Nunn A V W,et al.Molecular targets of cannabidiol in neurological disorders[J].Neurotherapeutics,2015,12(4):699-730.
[37]Wang Y,Mukhopadhyay P,Cao Z,et al.Cannabidiol attenuates alcohol-induced liver steatosis,metabolic dysregulation,inflammation and neutrophil-mediated injury[J].Sci Rep,2017,7(1):12064.
[38]Petrocellis L D, Nabissi M, Santoni G,et al.Actions and regulation of ionotropic cannabinoid receptors[J].Adv Pharmacol,2017,80:249-289.
[39]Mohammad R,Ghovanloo,Gregory N,et al.Inhibitory effects of cannabidiol on voltage-dependent sodium currents[J].J Biol Chem,2018,293(43):16546-16558.
[40]Howard P,Twycross R,Shuster J,et al.Cannabinoids[J].J Pain Symptom Manag, 2013,46(1):142-149.
[41]Mcpartland J M,Duncan M,Di Marzo V,et al.Are cannabidiol and tetrahydro cannabivarin negative modulators of the endocannabinoid system?A systematic review[J].Br J Pharmacol,2015,172(3):737-753.
[42]Hoon H K,Sunny L,Jewon R,et al.CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages[J].Cardiovasc Res,2009,84(3):378-386.
[43]Laprairie R B,Bagher A M,Kelly M E M,et al.Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor[J].Br J Pharmacol,2015,172(20):4790-4805.
[44]Muller C,Morales P,Reggio P H.Cannabinoid ligands targeting TRP channels[J]. Front Mol Neurosci,2018,11:487.
[45]Pertwee RG.The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids:Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin[J].Br J Pharmacol,2008,153(2):199-215.
[46]蒙虎,黃岸,蒙一純.一種對(duì)皮膚損傷修復(fù)和護(hù)理的水溶液及其制備方法[P].北京市:CN111939170A,2020-11-17.
[47]蒙一純,黃岸,蒙虎.一種對(duì)皮膚損傷修復(fù)和護(hù)理的醫(yī)用冷敷貼及其制備方法[P].北京市:CN112007018A,2020-12-01.
[收稿日期]2021-02-18
本文引用格式:黃岸,蒙虎,關(guān)林,等.大麻二酚在皮膚健康中的作用[J].中國(guó)美容醫(yī)學(xué),2022,31(3):181-185.